Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hims & Hers Health (DE:82W)
FRANKFURT:82W
Hims & Hers Health (82W) Stock Price & Analysis
2 Followers
82W Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€5.36 - €24.02
Previous Close€19
Volume100.00
Average Volume (3M)1.98K
Market Cap
€4.11B
Enterprise Value€3.92B
Total Cash (Recent Filing)$221.00M
Total Debt (Recent Filing)$9.95M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Aug 05, 2024EPS Estimate
€0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding214,786,086
10 Day Avg. Volume2,193
30 Day Avg. Volume1,979
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)22.17
Price to Sales (P/S)16.58
Price to Cash Flow (P/CF)54.10
P/FCF Ratio35.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.49
Enterprise Value/Gross Profit5.48
Enterprise Value/Ebitda212.26
Forecast
1Y Price Target
€19.04Price Target Upside0.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Hims & Hers Health News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRaising 2Q rev to $315M and EBITDA to $38M based on app utilization analysis.
Growth And DifferentiationRemain optimistic on HIMS’ long-term growth trajectory driven by product differentiation and a strong brand.
Market OpportunityHIMS has a real opportunity to take significant share as a compounding pharmacy for GLP-1 prescriptions.
Bears Say
Financial PerformanceMarch witnessed the first month-over-month decline in Monthly Active Users since December 2021.
Operational ChallengesManagement acknowledged potential friction when drugs are removed from the FDA shortage list.
Regulatory RisksThe FDA is increasing scrutiny of compounded GLP-1s, and major pharmaceutical companies have been taking legal action against what they consider counterfeit drugs.
---
Ownership Overview
37.51% Insiders
16.14% Mutual Funds
13.59% Other Institutional Investors
32.76% Public Companies and
Individual Investors
Website Traffic
The estimated number of people who visited one or more of the websites owned by Hims & Hers Health
Desktop Users
Mobile Users
82W FAQ
What was Hims & Hers Health’s price range in the past 12 months?
Hims & Hers Health lowest stock price was €5.36 and its highest was €24.02 in the past 12 months.
What is Hims & Hers Health’s market cap?
Currently, no data Available
When is Hims & Hers Health’s upcoming earnings report date?
Hims & Hers Health’s upcoming earnings report date is Aug 05, 2024 which is in 29 days.
How were Hims & Hers Health’s earnings last quarter?
Hims & Hers Health released its earnings results on May 06, 2024. The company reported €0.047 earnings per share for the quarter, beating the consensus estimate of €0.009 by €0.037.
Is Hims & Hers Health overvalued?
According to Wall Street analysts Hims & Hers Health’s price is currently Undervalued.
Does Hims & Hers Health pay dividends?
Hims & Hers Health does not currently pay dividends.
What is Hims & Hers Health’s EPS estimate?
Hims & Hers Health’s EPS estimate is €0.04.
How many shares outstanding does Hims & Hers Health have?
Hims & Hers Health has 206,408,460 shares outstanding.
What happened to Hims & Hers Health’s price movement after its last earnings report?
Hims & Hers Health reported an EPS of €0.047 in its last earnings report, beating expectations of €0.009. Following the earnings report the stock price went up 6.603%.
Which hedge fund is a major shareholder of Hims & Hers Health?
Among the largest hedge funds holding Hims & Hers Health’s share is Farallon Capital Management, L.L.C.. It holds Hims & Hers Health’s shares valued at 26M.
---
Hims & Hers Health Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€19.04 (0.23% Upside)
€19.04 (0.23% Upside)
Blogger Sentiment
Bullish
DE:82W Sentiment 90%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
133.74%
12-Months-Change
Fundamentals
Return on Equity
-0.72%
Trailing 12-Months
Asset Growth
19.08%
Trailing 12-Months
Company Description
Hims & Hers Health
Oaktree Acquisition Corp. is an emerging growth company, which engages in the provision of merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded by Patrick McCaney, Alexander Taubman and Mathew Pendo in 2019 and is headquartered in Los Angeles, CA.
---
82W Company Deck
---
82W Earnings Call
Q1 2024
0:00 / 0:00
---
82W Revenue Breakdown
96.60% Online
3.40% Wholesale
---
82W Stock 12 Month Forecast
Average Price Target
€19.04
▲(0.23% Upside)
Technical Analysis
Hims & Hers Health
―
Bausch Health Companies
―
Teva Pharmaceutical
―
Neurocrine
―
Sangamo Biosciences
―
Best Analysts Covering 82W
1 Year
1 Year Success Rate
7/7 ratings generated profit
1 Year Average Return
+99.50%
reiterated a buy rating 4 months ago
Copying Jack Wallace's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +99.50% per trade.
---